SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Classic TA Workplace
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: augieboo who wrote (48766)8/2/2002 1:58:29 PM
From: reaper  Read Replies (2) of 209892
 
<<Very long term, i.e., six months to a year or three, I won't be at all surprised to see 200 or below -- for FA reasons as much as anything. There are large parts of the bio industry which have no products, no profits, and not prospects. >>

Heard recently that 59% of biotech companies have less than 2 years of cash and 33% have less than 1 year of cash. Now, most of these are not in the BTK; BTK is full of stuff like Amgen or Genentech or Idec that is very free cash positive. But a lot of this little sh8t is gonna go away.

For an example, take Alkermes (ALKS). $161mm in cash, and a $200mm convertible note (so on a net basis they are $40mm or so in debt). in the last twelve months they have gone through $167mm in cash. they are projected to lose a buck next year; with 65mm shares that's another $65mm out the door. i just happen to know this one as i had been short, covered at $4+ a handful of weeks ago and re-shorted the spike yesterday. But there are a lot of biotechs that look like this.

Cheers
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News